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PeroralAbstract In the modern world, a number of therapeutic proteins such as vaccines, antigens, and
hormones are being developed utilizing different sophisticated biotechnological techniques like
recombinant DNA technology and protein puriﬁcation. However, the major glitches in the optimal
utilization of therapeutic proteins and peptides by the oral route are their extensive hepatic ﬁrst-pass
metabolism, degradation in the gastrointestinal tract (presence of enzymes and pH-dependent fac-
tors), large molecular size and poor permeation. These problems can be overcome by adopting tech-
niques such as chemical transformation of protein structures, enzyme inhibitors, mucoadhesive
polymers and permeation enhancers. Being invasive, parenteral route is inconvenient for the admin-
istration of protein and peptides, several research endeavors have been undertaken to formulate a
better delivery system for proteins and peptides with major emphasis on non-invasive routes such as
oral, transdermal, vaginal, rectal, pulmonary and intrauterine. This review article emphasizes on the
recent advancements made in the delivery of protein and peptides by a non-invasive (peroral) route
into the body.
ª 2014 Production and hosting by Elsevier B.V. on behalf of King Saud University. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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Proteins and peptides are the building blocks of life and are
now evolving as a very promising brand of therapeutic entities.
Once a rarely used subset of medical treatments, therapeutic
proteins have increased dramatically in number and frequency
of use since the introduction of ﬁrst recombinant protein ther-
apeutic viz. human insulin, 25 years ago. Therapeutic proteins
and peptides hold a signiﬁcant role in almost every ﬁeld of
medicine, but this role is still only in its infancy. The founda-
tion for the popularity of protein therapeutics was laid down
with the regulatory approval of recombinant insulin by the
US Food and Drug Administration (FDA) in 1982, which
became the ﬁrst commercially-available recombinant protein
and a source of major therapy for patients suffering from dia-
betes mellitus (Leader et al., 2008). Three decades have passed
since the inauguration of approval of ﬁrst recombinant protein
i.e. insulin by the FDA, and its clinical success has inspired the
ﬁeld of therapeutic proteins into a wider horizon ever since,
with more than 130 different proteins or peptides already
approved for clinical use by the FDA till 2008 alone, and many
more in the development pipeline.
A better understanding of molecular biology and biochem-
istry behind the macromolecular endogenous proteins, pep-
tides and peptidergic molecules, and their role in various
body functions and pathological conditions has led to therealization of the enormous therapeutic potential of proteins
and peptides in the last few decades. Consequently, a variety
of new therapeutic proteins have been developed showing
therapeutic beneﬁts in the treatment of ailments like diabetes,
cancer which offer several advantages over the conventional
small-molecule drugs. Firstly, proteins often serve a highly spe-
ciﬁc and complex set of functions in the body that cannot be
mimicked by simple chemical compounds. Secondly, since
the action of proteins is highly speciﬁc, there is often less
potential for therapeutic protein to interfere with normal bio-
logical processes and cause adverse effects. Thirdly, because
the body naturally produces many of the proteins that are used
for therapeutic purpose, these agents are often well-tolerated
and are less likely to elicit immune responses. Fourthly, for dis-
eases in which a gene is mutated or deleted, protein therapeu-
tics can provide an effective replacement for the treatment
without the need for gene therapy, which is not currently avail-
able for most genetic disorders. Fifthly, the clinical develop-
ment and FDA approval time of protein therapeutics may be
faster than that of small-molecule drugs. A study published
in 2003 showed that the average clinical development and
approval time was more than one year faster for 33 protein
therapeutics approved between 1980 and 2002 than for 294
small-molecule drugs approved during the same time period.
Lastly, because proteins are unique in form and function, com-
panies are able to obtain far-reaching patent protection for
protein therapeutics. The last two advantages make proteins
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with small-molecule drugs (Leader et al., 2008).
As a result of intensive research efforts in both academic
and industrial laboratories, recombinant DNA, protein and
peptide engineering and tissue culture techniques can now be
used to obtain proteins and peptides for therapeutic use on a
commercial scale which resemble an endogenous molecule
and thus provoke fewer or minimal immunological responses.
Though the initial problems related to obtaining non-immuno-
genic protein therapeutics in purer form at commercial scales
have been overcome to quite some extent, their formulation
and optimum delivery still remains the biggest challenge to
pharmaceutical scientists. There are now many examples
(Octreolin, Sandimmune, AI-401, HDV-I, Capsulin,
Oraldel, IN-105, Oral-Lyn, CLEC, ORMD-0801,
Eligen etc.) in which proteins have been used successfully
for therapeutic purposes (mentioned in detail later in this
review under clinical applications). Nonetheless, potential pro-
tein therapies that have failed so far outnumber the successes,
in part owing to a number of challenges that are faced in the
development and use of protein therapeutics.
Route of administration is a critical factor in any therapeu-
tic intervention which governs both the pharmacokinetics and
efﬁcacy of the drug. For protein and peptide therapeutics, an
interplay of poor permeability characteristics, luminal, brush
border, and cytosolic metabolism, and hepatic clearance mech-
anisms result in their poor bioavailability from oral and non-
oral mucosal routes. Hence, at present these drugs are usually
administered by parenteral route. However, inherent short
half-lives of penetrating peptides (PP) and almost warranted
chronic therapy requirements in a majority of cases make their
repetitive dosing a necessity. Frequent injections, oscillating
blood drug concentrations and low patient acceptability make
even the simple parenteral administration of these drugs prob-
lematic. This has prompted researchers to develop new deliv-
ery systems capable of delivering such a class of drugs in a
more effective manner. Although there have been reports of
successful delivery of various PP therapeutics across non-per-
oral mucosal routes, peroral route continues to be the most
intensively investigated route for PP administration. This
interest in the peroral route, despite enormous barriers to drug
delivery that exist in the gastrointestinal tract (GIT), can be
very well appreciated from obvious advantages such as ease
of administration, large patient acceptability, etc. Potential
cost savings to the health care industry further augment the
advantages of peroral systems in terms of patient compliance
and acceptability, since peroral formulations do not require
sophisticated sterile manufacturing facilities or the direct
involvement of health care professionals.
There is a need to design an approach which not only pro-
tects the protein/peptide from enzymatic degradation but also
aids in enhancing its absorption without altering its biological
activity (Gupta et al., 2013). Although the oral delivery of pro-
teins and peptides remains an attractive option, but to reach its
true potential the challenges must be met. Oral delivery of pro-
teins and peptides has long been hailed as the ‘Holy Grail’ of
drug delivery by showing great potential but also presenting
problems in their development (Shen, 2003).
The current article deals with the possibilities being
explored in the oral delivery of protein and peptide therapeu-
tics, the challenges in their development and the current and
future prospects, with focus on technology trends in themarket to improve the bioavailability of proteins and peptides
and effect of different forms of therapeutic proteins by oral
routes.2. Peroral route: promises and pitfalls
Oral delivery is the most sought after route of administration
for most of the drugs and pharmaceutical products, which
depends on the drug’s molecular structure or weight
(Elsayed et al., 2009). Bioavailability is dependent upon the
molecular mass of drugs if molecular mass increases above
500–700 Da, bioavailability of drugs decreases sharply
whereas bioavailability is essentially independent of molecular
mass for drugs of less than 500–700 Da (Donovan et al.,
1990). Proteins have important therapeutic roles, such as insu-
lin which is a major therapeutic agent for the management of
insulin-dependent diabetes mellitus (Type 1) and for many
patients with non-insulin dependent diabetes mellitus (Type 2)
(El-Sayed et al., 2007; Khan, 2003). Intestinal mucosa is con-
sidered as a very complex structure. On the basis of adhesion
in gastrointestinal tract, there are two main targeting areas,
i.e. mucosal tissue and mucus gel layer. It may be due to
adhesive interaction with mucoadhesive polymers either
through non-speciﬁc (Van der waal and hydrophobic interac-
tion) or speciﬁc interaction between complementary struc-
tures. On the other hand, regular renewal of mucosal
surface by a turnover process restricts muco-adhesive drug
delivery system (Ponchel and Irache, 1998). Currently, phar-
maceutical strategies aim to increase the bioavailability, over-
come the enzymatic degradation, enhance the permeability
and develop safe, efﬁcacious and highly-potent proteinous
drugs (Hamman et al., 2005; Shah et al., 2002) Proteins have
been transported (actively) through the epithelial lining of the
small intestine in membrane-bound vesicles after binding to
the cell-surface receptor. Very few portions are released at
the baso-lateral membranes and then secreted in the intact
form in the intestinal space. (Strous and Dekker, 1992). Drug
absorption depends upon the age, diet and disease state
(Morishita and Peppas, 2006). Mucus covers the epithelial cell
surface, hence hampering the diffusion of peptide drugs. The
goblet cells continuously secrete highly viscous gel whose vis-
cosity enhances strongly towards the cell surface (Camenisch
et al., 1998). Protein and peptides most commonly follow the
paracellular route as compared to transport through the
lipophilic cell membrane. Metabolic barriers consist of brush
border peptidases and luminal proteases such as trypsin,
a-chymotrypsin, elastase and carboxypeptidase. These
enzymes easily degrade the therapeutic proteins and peptides
administered through oral routes. Recently, there are only
two oral proteins and peptides, e.g. Interferon-a and Human
growth hormone (HGH) in clinical developmental stage
(Orive et al., 2004) FDA has approved three drugs which aug-
ment glucagon like peptide-1 (GLP-1) production, on the
basis of incretin based therapy for potential treatment in Type
2 Diabetes mellitus (Peters, 2010). It was reported that the
intestinal uptake of therapeutic protein through biodegrad-
able nanoparticles was enhanced by particle size reduction
(enhanced dissolution) (Bakhru et al., 2013).
Insulin releases from pancreatic b-cells into the hepatic por-
tal vein and then into the liver which is the primary site of
action, whereas, parental route and other delivery systems
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the systemic circulation. In this delivery system, the drug
reaches the systemic circulation bypassing the ﬁrst-pass metab-
olism, but in case of oral delivery, insulin ﬁrst reaches the liver
(20% of drug dose is available in liver) and then to the periph-
eral tissue. Oral route of administration is closer to the natural
physiological route of insulin (Rekha and Sharma, 2013).
2.1. Transport mechanism of macromolecules
Large numbers of mechanisms are responsible for penetration
such as simple diffusion (paracellular and transcellular), car-
rier-mediated transport, active transport and pinocytosis or
endocytosis (Salamat-Miller et al., 2005). Proteins and peptides
have very low logP (<0) value. Those drugs have lack of lipo-
philicity, no passive absorption can take place and are absorbed
through paracellular pathways (restricted to small molecules,
less than 100–200 Da) (Camenisch et al., 1998). The paracellu-
lar space lies between 10 and 30–50A˚, therefore the paracellular
route is not feasible for large macromolecules. But in the case of
insulin, it is adsorbed on the apical membrane and is internal-
ized by speciﬁc types of endocytosis processes (Agarwal and
Khan, 2001). Few numbers of protein and peptides show prac-
tically active transport by binding to the cell surface receptor or
binding sites in the epithelial lining of the small intestineFigure 1 (A) Transport mechanism of biodrug through the intestin
enhancer, and (C) enzyme inhibitors, (D) Representative mechanism o(membrane bound vesicles) (Bastian et al., 1999). The most
commonly used transport mechanism is passive diffusion with
two ways of transport: ﬁrst, paracellular (transport of drug
through the intercellular space between the cells) and second,
transcellular (involves passage into or across the cells), and is
shown in Figure 1A. Transportation of drugs depends on over-
all molecular geometry, lipophilicity and charge of the trans-
port pathway across the oral mucosa (Brayden and Mrsny,
2011). A minimum level of lipophilicity is essential in drugs
to partition into the epithelial membrane and absorbed through
transcellular passive diffusion (Camenisch et al., 1998). Trans-
port of therapeutic molecules from the gastrointestinal tract
into the systemic circulation is through the mucosal layer then
through the areolar layer. Other two intestinal layers (areolar
or submucosal) connect together the mucus and muscular lay-
ers (Blanchette et al., 2004). Muscular and mucus layers are the
strongest layers of the intestine which consists of the loose, ﬁl-
amentous areolar tissue containing lymphatics, nerves and
blood vessels (Rekha and Sharma, 2013).
Membrane perturbing in order to increase transcellular per-
meation, was shown on human Caco-2 epithelial cell monolay-
ers when exposed atmaximum concentration and demonstrated
tolerance in vitro, but the bestway is to attach any ligand onmol-
ecules that opens the tight junctions (Brayden andMrsny, 2011;
Aungst, 2000).al epithelium membrane, (B) Probable mechanism of penetration
f prodrug absorption and its activation.
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The unfriendly physiochemical properties of proteins and pep-
tides have created great challenges for the formulation scien-
tists, and have therefore resulted in a need to develop other
routes of administration, such as oral, nasal, buccal, pulmon-
ary, transdermal, rectal and ocular (Park et al., 2011). Use of
proteins and peptides as therapeutic agents is limited due to
lack of an effective route and method of delivery. Various crit-
ical issues associated with therapeutic protein and peptide
delivery, that have drawn the attention of formulation scien-
tists include the following:
(i) Proteins and peptides are high molecular weight bio-
polymers which serve various functions, such as
enzymes, structural elements, hormones or immuno-
globulins, and are involved in several biological activi-
ties. However, large molecular weight, size and
presence of both hydrophilic and hydrophobic append-
ages in their structure, render proteins difﬁcult to enter
into cells and other body compartments, and thus
impart poor permeability characteristics through vari-
ous mucosal surfaces and biological membranes. Com-
monly, therapeutic proteins and peptides are
hydrophilic with a logP< 0 (Camenisch et al., 1998).
(ii) Many therapeutic proteins and peptides are efﬁcacious
in large part because of their tertiary structure, which
can be lost under various physical and chemical environ-
ments, resulting in their denaturation or degradation
with a consequent loss of biological activity, thereby
making these molecules inherently unstable.
(iii) Many proteins and peptides have very short biological
half-lives in vivo due to their rapid clearance in liver
and other body tissues by proteolytic enzymes, pro-
tein-modifying chemicals or through other clearance
mechanisms.
(iv) Protein and peptide degradation is highest in the stom-
ach and duodenum and is signiﬁcantly decreased in the
ileum and colon. Various delivery systems have been
developed to target absorption from the colon and ileum
as a result, and minimize exposure of drug to proteolytic
enzymes. Thick enteric coating formulation has been
used to target both the ileum and colon due to delay
in the release of drug for a sufﬁcient period of time.
However there is an additional drawback such as poten-
tial changes in colon microﬂora, delay drug absorption
and risk of absorption, along with drugs with endotox-
ins and other potentially harmful compounds residing
in this intestinal region (Rubinstein, 1995; Van den
and Kinget, 1995).
(v) As proteins and peptides deliver speciﬁc actions and are
highly potent, a precise clinical dosing is of utmost
importance.
(vi) The body may mount an immune response against the
therapeutic protein and peptide. In some cases, this
immune response may neutralize the protein and even
cause a harmful reaction in the recipient. Recombinant
technology and other advances have allowed the devel-
opment of various antibody products that are less likely
to provoke an immune response than unmodiﬁed
murine antibodies, because in humanized antibodies,portions of the antibody that are not critical for anti-
gen-binding speciﬁcity are replaced with human Ig
sequences that confer stability and biological activity
on the protein, but do not provoke an anti-antibody
response. Exclusive human antibodies can be produced
using transgenic animals or phage display technologies.
(vii) For a protein to be physiologically active there is a need
for some post-translational modiﬁcations, such as glyco-
sylation, phosphorylation and proteolytic cleavage.
These requirements may dictate the use of speciﬁc cell
types that are capable of expressing and modifying the
proteins appropriately. Thus, recombinant proteins can
be synthesized in a genetically-engineered cell type for
large-scale production.
(viii) The costs involved in developing therapeutic proteins
and peptides are high due to the expensive intermediate
technologies involved in their designing (Leader et al.,
2008; Mahato et al., 2003).
Penetration of drug through oral mucosa into systemic cir-
culation is a major hindrance in their absorption. A hydro-
philic large molecular weight drug such as protein and
peptides are easily degraded by oral route, as a result they
are not or very less available in the systemic circulation
(Mahato et al., 2003; Antunes et al., 2013). Aoki et al.
(2005) demonstrated through his in vitro studies that the mucus
layer plays a critical role in the absorption of insulin across the
small intestinal. In these studies mucus layers are removed
from the intestinal segments using hyaluronidase without
affecting the integrity of the epithelial part of the intestine.
The transportation of therapeutic protein through hyaluroni-
dase-treated small intestine was found to be signiﬁcantly
higher in comparison to the control group treated with phos-
phate buffered saline, PBS (Aoki et al., 2005).
3. Formulation approaches for oral delivery of proteins and
peptides
The two important approaches for formulation of protein and
peptides by oral route include: use of absorption enhancers
and enzymatic inhibitor. Being charged, large in size and
hydrophilic, proteins and peptides are notoriously poor perm-
eators (and thus exhibit poor oral bioavailability per se). The
former approach offers an opportunity to counter balance this
permeation problem of therapeutic proteins. The latter
approach is an answer to the instability exhibited by proteins
on account of a plethora of proteolytic enzymes present in
the GIT which have inherent dietary protein-digesting func-
tions. Various strategies for the development of oral protein
and peptides are given below.
3.1. Enzyme inhibitors (protease inhibitors)
Macromolecules, such as proteins and carbohydrates, are bro-
ken down in the digestive system into simpler molecules, viz.
amino acids and sugars, respectively, which are easily absorbed
because intact protein absorption is typically minimal (<1%)
(Iyer et al., 2010). Various types of enzymes (endopeptidases
and exopeptidases) are responsible for the cleavage of amino
acid chains, (e.g. trypsin, chymotrypsin, elastase, pepsin and
carboxypeptidases etc.). Each type of enzyme is speciﬁc for
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targeted inhibitors (Lueben et al., 1996; Bernkop-Schnurch
et al., 1997; Gamboa and Leong, 2013). First approach is
the use of enzyme inhibitors such as aprotinin and soybean
trypsin inhibitors, camostat mesilate and chromostatin, but
administration of such types of protease inhibitors for long
duration results in the deﬁciency of these enzymes in humans
(Figure 1C) (Yamamoto et al., 1994; Tozaki et al., 1997). A
novel class of enzyme inhibitor, chicken and duck ovomucoids
has been recently reported, and a formulation has been devel-
oped wherein the insulin and duck ovomucoids offered 100%
protection against the action of trypsin and a-chymotrypsin
(Agarwal and Khan, 2001). In another case study, polymer
inhibitor conjugates such as carboxymethyl cellulose-Elastinal
(CMC-Ela) have shown in vitro protection against enzymes
trypsin, a-chymotrypsin and Elastase. After 4 h of incubation,
nearly 33% of the therapeutic protein was found to be active
against the elastase (Park et al., 2011; Marschutz and
Bernkop-Schnurch, 2000).
Serpin (Serine protease inhibitor) forms covalent complexes
with the target protease and in such a way, the protein is pro-
tected from the protease enzymes. On the basis of structural
studies, it has been demonstrated that inhibitory members of
the group undergo conformational changes, known as stressed
and relaxed transition, and conformational change which is the
critical step in the mechanism of inhibition of a targeted
protease (Egelund et al., 1998).
3.2. Absorption enhancers (permeation enhancers)
Penetration enhancers (PEs) directly transport protein mole-
cules through the epithelium without major effects on their sol-
ubility (Brayden and Mrsny, 2011). PEs are commonly
classiﬁed as either tight junction (TJ) selective, in order to
increase paracellular permeability through slight modiﬁcation
of TJ functional properties or in order to increase transcellular
permeation (membrane perturbing). These mechanisms ascer-
tained using human Caco-2 epithelial cell monolayer at the
maximum concentration in which the systems can tolerate
in vitro conditions. In early 1990s, there was some consensus
that the smarter strategies for poorly permeable drugs were
to opt for speciﬁc agents, that opened the tight junction of
the epithelial cell membrane, but the latter strategies suggested
that membrane perturbation was considered potentially toxic
(Maher et al., 2009). Enhancers have been studied for oral
insulin delivery, such as fatty acids and bile salts, which
enhance the permeability across the mucosal walls (Obata
et al., 2000). They open up the tight junctions reversibly and
improve the permeability of insulin and several other proteins
(Figure 1B). A novel absorption enhancer, viz. Zonula occlu-
dens toxin (ZOT) (Salama et al., 2006), chitosan (Prego
et al., 2005), thiolated polymers (Bernkop-Schnurch, 2005)
and Pz-peptide have all been studied as penetration enhancers
for oral insulin delivery, and have resulted in effective reduc-
tion of glucose levels in the body (Fasano and Uzzau, 1997).
Sachdeva et al. (1997) reported that proteases (pancreatic
enzymes) are less active against small peptides, such as cyclo-
sporine and vasopressin analogues (Sachdeva et al., 1997).
Leone-bay et al. (2001) described a new class of molecules that
alter the conformation of proteins reversibly and provide facil-
ity for their transport across mucosa (Leone-Bay et al., 2001).The most common drawback of penetration enhancers in the
case of long-term usage is that they may damage or even dis-
solve the biomembrane, leading to local inﬂammation (Iyer
et al., 2010).
Surfactants also enhance the transcellular transport by dis-
rupting the lipid bilayer and make it more permeable to drugs
(Lecluyse and Sutton, 1997), a mechanism very similar to that
of chelating agents which form a complex with calcium ions
and rupture the tight junctions and facilitate the transport of
proteins (Aungst, 2000; Park et al., 2011). When proteins
and peptides are given with lipophilic carriers, they enhance
their absorption (Sood and Panchagnula, 2001) such as insu-
lin, human growth hormone (HGH), calcitonin and recombi-
nant parathyroid hormone (Lee et al., 2005; Kidron et al.,
2004). The carrier alters the lipid solubility and then makes
access to pore of the integral membrane (Leone-Bay et al.,
2001). Merrion Pharmaceuticals (Dublin, Ireland) produced
a novel formulation of alendronate with paracellular penetra-
tion enhancer known as Almerol formally known as MER-
103. Almerol was found to have better bioavailability and
fewer side effects as compared to alendronate for the treatment
of osteoporosis (Walsh et al., 2011; Frost, 2008).
3.3. Mucoadhesive polymeric systems
They have a changing swelling behavior in response to the
environmental factors, such as ionic strength, electric ﬁeld,
light, temperature and pH (Park et al., 2011). The most com-
mon approach for the encapsulation of oral insulin is using
mucoadhesive polymers, such as chitosan (Mathiowitz et al.,
1997), poly [lactic-co-glycolic acid] (PLGA) (Damge et al.,
1988), thiolated polymer and alginate, which have been studied
extensively (Takka and Acarturk, 1999). Chitosan is a natural
non-toxic, biocompatible and biodegradable polymer (Hejazi
and Amiji, 2003). When a peptide (transforming growth factor
[TGF-b]) was delivered with chitosan, as a result, a 6–7-fold
enhancement of permeability of TGF-b with chitosan was
attained. This resulted in the healing of the oral mucosa by
arresting epithelial cell division and thus destruction of the
cells from the effects of anticancer therapy (Senel et al.,
2000). Mucoadhesive polymer adheres to the mucus and
increases the drug concentration gradient. When insulin was
encapsulated with Poly (methacrylic acid-g-ethylene gly-
col)[P(MAA-g-EG)], [P(MAA-g-EG)] being a pH sensitive
mucoadhesive polymer, showed pH-dependent swelling behav-
ior, as a result of formation or dissociation of inter-polymer
complex [MAA-g-EG] polymer and it showed 10% bioavail-
ability of orally-administered insulin encapsulated with pH
sensitive mucoadhesive polymer as compared to insulin
(Lowman and Peppas, 1997; Peppas and Klier, 1991). Thiolat-
ed polymers (thiols side chains) have strong mucoadhesive
properties due to covalent bonding with cysteine-rich subdo-
mains of the mucus glycoprotein (Leitner et al., 2003). Alone,
protein encapsulated in polymer did not show efﬁcient absorp-
tion as compared to polymer with enzyme inhibitor or protease
inhibitor. Encapsulation leads to successful protection of the
protein formulations from enzymatic degradation and also
gets successful results. Currently, only two peptide- and pro-
tein-based drugs (Interferon-a and human growth hormone
(hGH)) that can be given orally are known to be in clinical
development (Renukuntla et al., 2013).
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A large number of carriers for proteins and peptides delivery,
such as emulsions, nanoparticles, microspheres and liposomes,
have been used to protect the protein formulation against the
harsh environment of the GI tract (acidic medium and
enzymes). Emulsion developed by using lipophilic surfactant-
coated insulin decreased its degradation and increased its
permeation. The critical drawback of emulsions is its physio-
chemical stability (Toorisaka et al., 2003). Stability problem
of emulsions may be overcome by dry emulsion formulations,
which are prepared by spray drying, lyophilisation or evapora-
tion (Dollo et al., 2003). Liposomes have also been exploited to
improve the bioavailability of proteins from the intestinal tract
(Park et al., 2011). Liposomal system containing insulin and
sodium taurocholate markedly reduced the blood glucose lev-
els after oral administration and showed a high in vitro/in vivo
correlation in the Caco-2 cell model (Degim et al., 2004).
Langer and his colleagues developed polymerized liposomes
with covalent double bonds to improve the stability of biomol-
ecules against the harsh environments (Langer, 1998).
Carrier nanoparticles consisting of lipophilic polystyrene,
mucoadhesive chitosan and PLA-PEG were detected in both
epithelial and Peyer’s patches after inter-duodenal administra-
tion of drug molecules (Sakuma et al., 2001). Peyer’s patches
are the follicles of lymphoid tissue which contain M-cells. M-
cells have an important role in particle uptake. Particle size
and surface charge are important factors related to the uptake
of particulates by M-cells (Shakweh et al., 2005; Brayden et al.,
2005). Polymeric nanoparticles can be used to easily entrap
and encapsulate therapeutic proteins and peptides and lead
to the targeted area. It can be smoothly functionalized for
off opsonisation, and therefore has shown reduced toxicity
towards the non-target areas (peripheral tissues) (Chan et al.,
2010). Kafka et al. (2011) investigated the in vitro and in vivo
studies of gonadotropin releasing hormone-loaded nanoparti-
cles. Different in vitro conditions (artiﬁcial gastric juice, simu-
lated intestinal ﬂuid and brushtail possum plasma) were
studied, and it was found that less than 5% of the hormone
was released over 6 h in artiﬁcial gastric juice and simulated
intestinal ﬂuid, and 60% of it was released in brushtail possum
tail plasma over 1 h. In vivo study showed that sufﬁcient ther-
apeutic levels of these proteins were achieved from drug-
loaded nanoparticles in the systemic circulation.
It was investigated that mucoadhesive nanoparticles
increased the residence time of the drug moiety because it
allows the attachment of drug molecules into the mucous
membrane of GIT. The concepts behind these nanocarriers
can reduce clearance through the alimentary canal and lead
to increased bioavailability of therapeutic protein (Carvalho
et al., 2010). Makhlof et al. (2010) revealed the permeation-
enhancing properties of the mucoadhesive nanoparticles.
Fluorescein isothiocyanate dextran (FITC dextran) -loaded
polyelectrolyte complexes were prepared by interaction of
spermine, polyacrylic acid and FITC dextran. Confocal
microscopy has been investigated for prolonged penetration
using ﬂuorescein isothiocyanate dextran for in vitro and
in vivo conditions. It was concluded that the drug loaded
mucoadhesive nanoparticles showed prolonged penetration
(5–5.56-fold) as compared to free FITC dextran through con-
focal microscopy.3.5. Derivatization or chemical modiﬁcation of proteins and
peptides
Another approach is the derivatization of proteins and pep-
tides by using polyethylene glycol in order to protect the pro-
tein from enzymatic degradation and also to improve the
solubility (Clement et al., 2002). Lipidization, which is the
covalent interaction of hydrophobic moiety or non-covalent
conjugation with the hydrophobic moiety, results in the
increase in the hydrophobicity of proteins and peptides
(Goldberg and Gomez-Orellana, 2003). This approach has
been used in the clinic and has provided multiple drug candi-
dates. Some others are the formation of an inclusion complex
with leucine encephalin, protection of the peptides against
enzymatic degradation and also enhancement of absorption
(Basu et al., 2006). Chemical modiﬁcation can be done by
exploiting the carbohydrate moiety (glycoproteins) attached
to protein or side chain of protein (Calceti et al., 2004). The
deamination of ﬁrst amino acid and substitution of last L-Argi-
nine with D-Arginine along with simultaneous substitution of
fourth amino acid with valine forms 1-Deamino-8-D-Arginine-
Vasopressin (DDAVP). Such derivative forms of vasopressin
are two-times more potent than simple vasopressin (Shaji
and Patole, 2008). Transport of proteins and peptides have
been studied with and without absorption enhancers
(Morishita and Peppas, 2006) through buccal epithelia, for
example, TRH (Thyrotropin-releasing hormone) and the
LHRH (luteinizing hormone-releasing hormone) analogue
buserelin, a lauroyl tripeptide, the vasopressin fragment
DGAVP, and insulin resulting in increased bioavailability of
protein molecules (Jana et al., 2010).
3.6. Prodrug strategies
The prodrug is actually an active pharmacological moiety
which has been converted into inactive form through chemical
modiﬁcation, and when administrated changes into the active
form by enzymatic or non-enzymatic reactions (Figure 1D).
It is complete bioreversible cyclization (Jana et al., 2010).
These approaches enhance the solubility, permeability and
targeting of small molecules but it faces challenges, such as
limitation in methodology, stability of proteins and structural
complexity (Hsieh et al., 2009).
Drug + Carrier = ‘‘Prodrug’’ which after enzymatic deg-
radation gives free drug and carrier
A recent approach has enhanced the hydrophobicity and
targeting through a lipid raft which has been conjugated with
the protein moiety, as well as attached a speciﬁc transporter in
the parent drug (Renukuntla et al., 2013). Prodrug approach
may help in the absorption of various biomolecules such as
RNA, DNA, oligonucleotides and proteins (enzymes, protein-
ous drugs and hormones) (Vadlapudi et al., 2012). (Lue5)-
enkephaline was chemically-modiﬁed by phenyl propionic acid
into a prodrug, which was found to improve their permeability
across the Caco-2 1680-fold than the parent moiety (Cronauer
et al., 2003).
3.7. Novel approaches
Novel vesicular delivery systems containing bile salts are
known as ‘‘bilosome’’, which act as penetration enhancers
Table 1 Various approaches for oral delivery of therapeutic proteins.
Approach Examples Eﬀects on bioavailability Drawbacks References
Absorption enhancers Bile salts, fatty acids, Surfactants (anionic, cationic, and
nonanionic) chelators, Zonular OT, esters, cyclodextrin,





Available transport systems of both
proteins/peptides and undesirable
molecules in GIT
Brayden and Mrsny (2011)
Enzyme inhibitors
(protection against enzymes)
Sodium glycocholate, camostate mesilate, bacitracin soyabean,
trypsin inhibitor, CROVM, DKOVM, polymer inhibitor
conjugates, carbomers, polycarbophil, bestatin, aprotinin, and
streptozocin
Resisted enzymes
degradation in stomach and
intestines
Produced severe side eﬀects in the
treatment of chronic diseases such as
diabetes, etc.
Park et al. (2011), Iyer et al. (2010)
Mucoadhesive polymers P(MAA-g-EG) hydrogel microparticles, lectin–conjugated
alginate microparticles, thiolated polymer, natural
oligosaccharides gum, drum dried waxy maize starch, carbopol
974P, chitosan derivatives, sea curve 240, scleroglucan, HE-
starch, hydroxyl propyl cellulose, celloulose derivatives, pectin,




Limitation due to the mucus turnover in
absorption sites (intestine)




* Enteric coated o/w
Protection against acids and
enzymes
Physiochemical instability in case of
long term storage










Restrict release of protein to
favorable area of GIT









Derivatization of proteins Polyethylene glycol Protected against enzymatic
degradation as well as
enhanced the solubility
Non-speciﬁc pegylation Clement et al. (2002)
Endogenous cell carrier
system
Vitamin B12, transferrin, invasins, viral haemoaggulitinin,
toxin, and lectin
To enhance the intercellular
delivery system to target
cells, enhanced oral
absorption
Limited to transporting of small drugs. Bai et al. (2005); Morishita and Peppas (2006)
Cell penetrating peptides Proteins were enabled to be delivered into cells or tissues by
hybridizing with target molecules
Enhanced bioavailability
and targeting of proteins
Toxic eﬀect Morishita and Peppas (2006)
Prodrug approach Phenyl propionic acid Prodrug permeability
improved 1608fold than
parent drug
Lack of methodology, structural
complexity, stability problem of protein
Renukuntla et al. (2013), Hsieh et al. (2009)
Abbreviations: CROVM, Chicken ovomucoid; DEAE, Diethylaminoethyl cellulose; DKOVM, Duck ovomucoid; EDTA, Ethylenediaminetetraacetic acid; PLGA-PEG, Poly(lactic-co-glycolic) acid-













Table 2 Different nanocarrier systems and models for oral delivery of proteins.
Proteins Carrier system Models Reference
Insulin Nano-cubicles STZ-induced diabetic Rat Chung et al. (2002)
Insulin, calcitonin, HGF
(Human granulocyte colony stimulating factors)
Nanocapsules – Oppenheim et al. (1982)
Salmon calcitonin PLGA-nanoparticle Rat in vivo Sang and Park (2004)
Insulin Acrylic-based co-polymer
nanoparticles
STZ-induced diabetes in rat Foss et al. (2004)
Cyclosporine Lipid microemulsions Rat in vivo Constantinides (1995)
Leucine encephalin Sugar coupling with cellobiose
and gentiobiose
_ Mizuma et al. (1996)
Insulin Chitosan nanoparticles Alloxan–induced diabetic rat Pan et al. (2002)
HIV Protease (CGP57813) pH sensitive nanoparticles Rat in vivo Leroux et al. (1996)
DGAVP Niosomes – Yoshida et al., 1992
Abbreviations: DGAVP, desglycinamide-(Arg8)-vasopressin; HIV Protease (CGP 57813), is a peptidomimetic inhibitor of human immuno-
deﬁciency virus type 1 (HIV-1) protease; STZ, streptozocin.
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developed a gas-empowered delivery system for carbon diox-
ide-forced transport of the protein to the surface of the small
intestine. Insulin, together with a mucoadhesive polymer, tri-
methyl chitosan (a permeation enhancer) and polyethylene
oxide, was delivered with carbon dioxide gas to the surface
of the small intestine. This model enhanced the bioavailability
of insulin up to seven-fold (Sadeghi et al., 2009).
A novel conjugation of iron and polysaccharide multi-lay-
ered microcapsules was developed for the continuous release
of insulin (known as controlled delivery system). Multi-layered
insulin-loaded microcapsules were prepared through layer-by-
layer deposition of dextran sulfate and oppositely-charged
Fe+3(ferric ion) onto the surface of insulin microcapsules. In
this model, two oppositely-charged substances (dextran acts
as negatively-charged moiety and ferric ions act as the positive
moiety) adhere on the insulin and result in the formulation of
multi-layered insulin microcapsules (Zheng et al., 2009).
3.8. Novel functionality to macromolecules
3.8.1. Endogenous cell carrier systems
The endogenous carrier mechanisms are receptor-mediated
endocytosis and membrane transporters. In some cases, when
a drug is conjugated to a dipeptide, it gets detected by a pep-
tide inﬂux transporter, which in turn enhances its oral absorp-
tion (Morishita and Peppas, 2006). Efﬂux transport systems
such as P-glycoproteins lead to inefﬁcient bioavailability of
proteins and peptides, and therefore, certain P-gp inhibitors
are used with proteins and peptides to increase the bioavail-
ability (Varma et al., 2003). The membrane transport is possi-
ble for small drug molecules; whereas receptor-mediated
endocytic system does not have any limitation regarding the
size of the drugs (Morishita and Peppas, 2006). Receptor-
detectable ligands, such as vitamin B12, transferrin, invasins,
viral haemoaggulitinin, toxin and lectin, can be bound to
the protein molecules to enhance the intercellular delivery to
target cells (Russell-Jones, 2004; Lim and Shen, 2005). In
cases of oral delivery system of proteins and peptides such
as insulin and granulocyte colony-stimulating factors (G-
CSF), they are conjugated with transferrin carrier to improve
the bioavailability (Bai et al., 2005). There is a broad scope ofuse of recombinant fusion protein technology, and it may be
useful for the future development of oral and buccal delivery
systems for proteins and peptides (Table 1 and Table 2).
3.8.2. Cell-penetrating peptides (CPPs)
Cell-penetrating peptides (CPPs), also known as protein
transduction domains (PTD), are made up of 3–30 protein
residues (Munyendo et al., 2012). CPPs consist of two
groups, one is HIV-1 Tat peptide (cationic peptide) and arti-
ﬁcial oligoarginine, and the other group is penetratin derived
from Drosophila antennapedia homeoprotein (amhiphilic pep-
tides) (Nakase et al., 2008; Derossi et al., 1996). They are
employed to enhance the internalization of various biomole-
cules such as DNA, RNA, oligonucleotides, proteins and
peptides (De Coupade et al., 2005). A group of small pep-
tides such as TAT, oligoarginine and penetratin have been
used to internalize different protein and peptide formulations
into cells. The peptide enabled the delivery of the macromol-
ecules, microparticles, liposomes and nanoparticles into cells
or tissues by hybridizing with the target molecules. With
regard to the harmful effects of the peptides, TAT has been
shown to cause practically no toxic effects to membranes and
in most of the in vivo applications, no undesirable effect has
been detected (Zorko and Langel, 2005). It has been identi-
ﬁed that penetration occurred in the cell membrane and they
can cause a small disturbance in the membrane leading to
enhanced absorption of proteins and peptides through the
oral route. Peptide strategy is based on a non-speciﬁc deliv-
ery system, whereas it is proposed for the enhanced bioavail-
ability and targeting of proteins and peptides through the
oral route (Morishita and Peppas, 2006). Enhancement of
safety and efﬁcacy, and reduction in toxic effects are manda-
tory for the development of this delivery system for proteins
and peptides. By co-administering the typical CPP with the
insulin, enhanced intestinal bioavailability of insulin up to
30% was observed (Noriyasu et al., 2013).4. Clinical application of oral proteins and peptides
Oral delivery systems for proteins and peptides are still in
development stages. Oral delivery, being non-invasive, is the
Table 3 Technologies for oral delivery of proteins under clinical development by companies.
Company Product name Technology Formulation Development phase Product References
Apollo Life Science Oraldel Nanoparticles Tablet Clinical phase I b Insulin, TNF-blocker http://
apollolifesciences.com
Emisphere Eligen Penetration enhancers-
Salcaprozate sodium
Tablet Phase II Calcitonin, insulin, PTH, heparin,
calcitonin, enzymes (lipases, esterases,
proteases)
http://emisphere.com
Nobex/Biocon HIM2 Pegylation + PE Liquid Abandoned Insulin, enkephalin, calcitonin, PTH Wajberg et al., 2004
Oramed ORMD-0801
ORMD-0901
Salts of EDTA (enteric
coated + PE)




Liposomal insulin Tablet Phase II/III Insulin Schwartz et al., 2008
Diabetology Capsulin PE Capsule Phase II Insulin Whitelaw et al., 2005
Coremed Intesulin Nanoparticle
encapsulation




Vetsulin PE (sodium caprate
{C10})
Matrix tablet Phase I Insulin and GLP-1 analogues Walsh et al., 2011
Chiasma (Israel) Octreolin PE (sodium
caprylate{C8})








2011, Phase III completed Salmon calcitonin http://
tarsatherapeutics.com
Altus CLEC Protein crystallization Tablet Trial and error approach Calcitonin and other polypeptides Margolin (1996)
Generex Oral–Lyn  PE Spray devices and
aerosol particles
Phase IV Insulin, Macrotonin http://
www.generex.com
Endorex Orasome TM Polymerized liposome – Phase II Insulin, growth hormones, vaccines Okada et al., 1998
Provalis PLC MacrulinTM Lipid based
microemulsion
Emulsion Phase II Insulin, Salmon calcitonin Cilek et al., 2006
Eli–lily AI-401 Enzyme inhibitor Oral formulation Phase II Insulin http://
autoimmuneinc.com













Strategies for oral delivery of proteins and peptides 423most favored route of drug administration. This is illustrated
by the fact that oral delivery represents approximately US$
25 billion worldwide (Werle et al., 2007). Various techniques
for proteins and peptides delivery used by industries, are high-
lighted in this section (Table 3).
4.1. Eligen: Emisphere Technologies (USA)
This technology improves the transport of drugs through the
intestinal epithelium when a small carrier, (N-(8-(2-hydrox-
ybenzoyl) amino) caprylic acid), is attached non-covalently with
biomolecules, but the complex formation does not affect the
chemical properties of biomolecules and the interaction is
reversible. The drug-carrier complex is able to cross the epithe-
lial membrane and break the non-covalent bond between the
drug and carrier, because it occurs spontaneously by simple dif-
fusion on entering the blood circulation (Grosz et al., 2000; Wu
and Robinson, 1999). These techniques play an important role
in protection fromdigestive enzymes, aswell as impart enhanced
hydrophobic character to the macromolecules. Mostly, the
molecular size is in the range from 500 to 1500 Da (Walsh
et al., 2011). In pharmacokinetic studies it was found that Cmax
for insulin was reached after20 min from the time of adminis-
tration, and the insulin level returned to the baseline within
80–120 min. Two most recently developed acylated entities are
N-(8-(2-hydroxybenzoyl) amino) caprylic acid (SNAC) and
N-(5-cholorosalicyloyl)-8-aminocaprylic acid (5-CNAC).
SNACwas found to decrease transepithelial electrical resistance
in Caco-2 monolayers, as well as improve the release of lactate
dehydrogenase (LDH), suggesting that transcellular transport
enhancement can also be a part of its mechanism (Hess et al.,
2005). In vitro studies represented cytotoxicity in cell lines, but
in animal models did not show pathological changes. An oral
enteric-coated formulation for sCT (salmon calcitonin) has been
found to possess higher efﬁcacy than the nasal route of drug. In
2011, oral 5-CNAC/sCT failed in the phase III of clinical trials
(Karsdal et al., 2011). If higher doses of insulin are given to vol-
unteers then they showed a meaningful drop in HbA1c only
after 3 months of studies. The high dose makes the therapy
cost-effective and ensures the commercial viability of oral pro-
teins and peptides in themarketplace. At present, no clinical efﬁ-
cacy of such a system has been represented till date (Emisphere
Technologies, Inc., 2006).
4.2. ORMD-0801: Oramed Company (Jerusalem, Israel)
The technology came with enteric-coated oral capsules wherein
the protein part is released in the intestine with the help of pene-
tration enhancers (Craik et al., 2013). Effect of oral insulin was
determined by studies in eight volunteers in the fasted condition
and demonstrated reduced glucose levels (7–35%) and also a
decline in the C-peptide level (13–87%) in all formulations.When
the studies were conducted on fed volunteers, release of insulin
was found to be adversely affected by meal and GIT motility.
The onset and duration of action from time of administration
was found to be 2 h and 5–6 h, respectively (Walsh et al., 2011).
4.3. CLEC: Altus (USA)
Cross-linked enzyme crystal (CLEC) method mostly comprises
of two steps including, ﬁrst, batch crystallization of enzymesand second, crosslinking of enzyme microparticle (1–100 lm)
with cross-linking agents, such as glutaraldehyde. These above
two steps must be optimized in order to ensure efﬁcacy and
safety (Judge et al., 1998). Altus has produced different
CLEC enzyme products, such as lipases, esterase and prote-
ase, but they have certain risks. Crystallization of proteins is
not an easy step, therefore sometimes the crystalline state
may be inactive. Crystallization of biomolecules has several
advantages, viz. higher solubility of the crystalline form over
the amorphous form, easy puriﬁcation of protein and concen-
trated protein crystals being beneﬁcial for certain cases which
require high doses at the site of action (Margolin, 1996).
4.4. Oral-Lyn: Generex Biotechnology Corp. (Canada)
Oral-Lyn is delivered to the oral cavity through the Rapid-
mist device (aerosol-type device containing non-chloroﬂuro-
carbon propellant, penetration enhancers and stabilizers) to
the oral cavity which permeates across the buccal epithelium
and reaches the blood circulation (Bernstein, 2006).
Oral-Lyn delivery system has a sufﬁciently large micellar size
(larger than 7 lm), therefore, it does not enter the respiratory
system. A study was carried out to claim that Oral-Lyn is a
safe formulation in which Oral-Lyn without insulin formula-
tion was administrated to 40 dogs or nearly 1000 patients and
did not show any abnormalities in the buccal mucosa. These
formulations were found to be also effective in type-2 diabetes,
whose patients were resistant to diet, exercise, metformin, sul-
phonylureas and thiazolidenes. After the approval of Oral
Lyn in India for the purpose of import, commercialization,
marketing and sales for both types of diabetes, it has been
issued the license, where the product has been renamed as Oral
Recosulin (Shreya Life Sciences Pvt. Limited). Generex Bio-
technology has claimed that it is close to completing the Indian
clinical study needed to secure commercialization approval
from the Central Drugs Standard Control Organization
(CDSCO), Directorate General of Health Services, Ministry
of Health and Family Welfare, and is awaiting advice from
Shreya Life Sciences as to the anticipated timing of these initia-
tives. Generex Biotechnology Corp. has recently launched the
Oral Recosulin for the treatment of Type-1 and 2 diabetes
since 2009 (Generex biotechnology corporation, 2009).
4.5. IN-105: Nobex and Biocon (India)
Nobex technology (HIM2) is used in an oral delivery system
which has been developed by Biocon. In this technique,
enhancement of the hydrophobic character of proteins is
achieved by chemical modiﬁcation of insulin with a small PEG
and penetration enhancers. New modiﬁed analogue called IN-
105, which is an advanced new generation molecule to HIM2
(hexyl-insulin mono-conjugate 2) was prepared (Wajberg
et al., 2004). Introducing hydrophobicity to proteins by simple
chemical linkage of the primary amine group of the Lys-29 res-
idue in the beta chain of insulin and amphiphilic oligomer
resulted in enhanced transcellular transportation, increased
protein stability and resistance to enzymatic degradation when
administrated as oral semisolid hard gelatin capsules (Clement
et al., 2002; Kipnes et al., 2003). A study was conducted on 20
patients with T2DM (Type-2 diabetes mellitus) poorly-con-
trolled on metformin. The doses given were as follows: 10, 15,
424 A. Muheem et al.20, 30 mg of IN-105 and were compared with the placebo con-
trol arm. The study concluded that the onset of action occurred
10 min after administration of IN-105 and duration of action
was near about 1.5–2 h. Biocon did phase IV trials for IN-105
and marketed it as Insugen in India (Kumar, 2009).4.6. Oraldel: Apollo Life Sciences (Australia)
Studies on Oraldel delivery system showed that it protects
and transports biomolecules (insulin), which are encapsulated
inside them. The nanoparticles are composed of carbohy-
drate-based sugar (Rieux et al., 2005), protected polymer
coated with cyanocobalamin (Vitamin B12) (Petrus et al.,
2007). These formulations have the ability to entrap 100%
protein with vitamin B12, and as a result they protect proteins
from enzymatic degradation, as well as enhance the transpor-
tation of proteins (Park et al., 2011). Various sizes of insulin
nanoparticles are delivered by Apollo Life Sciences. Other cat-
egories of drugs, such as TNF blockers for the treatment of
rheumatoid arthritis, are under development stages. The global
market of anti-TNF was almost US $ one trillion in 2006,
growing at over 30% per year (Craik et al., 2013; Apollo life
sciences, 2010).
4.7. Capsulin: Diabetology (Jersey, UK)
In UK, Capsulin is under clinical trials by Diabetology,
which shows the onset of action within 30 min and duration
of action up to 4–6 h. During the fasting condition, higher
doses (300 I.U.), given to healthy volunteer with T1DM
(Type-1 diabetes mellitus), showed a sudden fall in blood glu-
cose level (1.6 mmol/l) and minimum doses (150 I.U.) which
represented lowering of blood glucose levels (0.02 mmol/l).
On the basis of clinical trial data, it was found that Capsulin
has the ability to control the progression of diabetic conditions
(Schwartz et al., 2008).
4.8. HDV-1: Diasome Pharmaceuticals (USA)
The concept of liposomal (vesicular) delivery system is growing
by Diasome Pharmaceuticals. It is available in non-invasive
(oral) and invasive (subcutaneous) forms. The study of 6 vol-
unteers (with T2DM- Type-2 diabetes mellitus), which was
based on comparison between placebo and doses in the rang-
ing trial of oral HDV-1, represented signiﬁcantly lowered
mean and increased PPG area curve as determined over a per-
iod of 14 h as compared with placebo, which demonstrated
non-linearity. The position of this drug is not clear due to
insufﬁcient data of pharmacokinetics. If HDV-1 is used for a
long duration, it becomes tough to control over-glycemic levels
due to the development of resistance (Skyler et al., 2005).
4.9. AI-401: Eli-Lily (USA)
Eli-Lily is still developing AI-401 for the oral delivery of pro-
teins (recombinant product of human insulin). Besides Oral-
Lyn andHIM2, AI-401 is used for the prevention and treatment
of Type-1 diabetes. This technique uses the concept of oral-tol-
erance therapy. The data of Type-1 diabetes are organized by the
oral insulin arm of NIH-sponsored diabetes prevention and isadvantageous for type-1 diabetes patients (www.accessdata.fda.
gov, 2003; http://www.auto mmuneinc.com).
4.10. Sandimmune: Novartis Pharmaceuticals (USA)
Sandimmune is a brand of Novartis, which consists of a
small hydrophobic cyclic polypeptide of 11 amino acids called
cyclosporine, and is available in the form of a capsule. It is
used as an immunosuppressant for organ transplant rejection
in kidney, liver and heart, as well as for the treatment of
auto-immune diseases (psoriasis and rheumatoid arthritis)
(Holt et al., 1995). It has a speciﬁc chemical structure of cyclo-
sporine, therefore absolute bioavailability is about 30%. The
uptake of cyclosporine is easy from intestine, and they are pro-
tected from enzymatic action due to its lipophilicity and
unique structure of the molecules. When cyclosporine contacts
with the aqueous environment it immediately forms a micro-
emulsion (Salama et al., 2010).
4.11. Octreolin: Chiasma (Israel)
Transient permeability enhancer (TPE) system is an enteric-
coated formulation which facilitates intestinal absorbance of
drug molecules with limited intestinal bioavailability. It is
formulated from sodium caprylate (C8) in hydrophobic
microparticles and is agitated with castor oils or medium-chain
glycerides, yielding emulsions (oily suspension)
(www.chiasmapharma.com). The FDA has approved the
orphan status for the Octreotide formulation, Octreolin.
During the phase III trials it (Octreolin) showed no side
effects in all the 12 individuals. Most effective molecular
weight of biomolecules that enhanced the permeation of
(TPE) is 4–10 KDa (Carino et al., 2000). C10 and C12 have
more promoting action than C8, in emulsion as an additive
and its combination, to give TPE (www.chiasmapharma.com).
5. Conclusion and future prospects
Oral delivery of proteins and peptides is the most efﬁcient way
to replace the invasive route as well as a very interesting and
promising area for research. The strategy for development of
oral biomolecules has always been challenged for the research-
ers due to their high molecular weight, chemical or enzymatic
degradation, and impermeability through the intestinal
mucosa. The growing ﬁeld of biotechnology has allowed
cost-effective and pilot-scale production of proteins and pep-
tides and it is used for oral delivery. In recent times, large num-
bers of proteins are invented through the oral route such as
Oral Recosulin, Octreolin and Sandimmune etc., in which
a few are in clinical stage of development. As discussed in the
review, nanotechnology offers various efﬁcient carriers for the
delivery of proteins such as solid lipid nanoparticles, nano-
structured lipid carrier, liposomes, niosomes, cubosomes and
nanoparticles, etc. Various efﬁcient approaches were discussed
for formulation development of oral delivery of therapeutic
proteins and it can be implemented in large-scale production.
Protein stability during formulation, and the product develop-
ment costs remain major challenges in pilot scale-up of these
novel products which need to be addressed at all levels of
research and development for this novel technology to be suc-
cessfully transferred from the bench to the bedside.
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